CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2024 Aug 13

PMID 39136283

Authors

Yang Wen

Xue Sun

Lingge Zeng

Shumei Liang

Deyu Li

Xiangtian Chen

Fanrui Zeng

Chao Zhang

Qiongyao Wang

Qinsong Zhong

Ling Deng

Linlang Guo

Affiliations

Soon will be listed here.

Abstract

Small cell lung cancer (SCLC) is characterized by rapid development of chemoresistance and poor outcomes. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) are widely used in breast cancer and other cancer types. However, the molecular mechanisms of CDK4/6 in SCLC chemoresistance remain poorly understood. Here, Rb1, Trp53, Pten (RTP) and Rb1, Trp53, Myc (RPM) spontaneous SCLC mouse models, SCLC cell line-derived xenograft (CDX) models, and SCLC patient-derived xenograft (PDX) models are established to reveal the potential effects of CDK4/6is on SCLC chemoresistance. In this study, it is found that CDK4/6is palbociclib (PD) or ribociclib (LEE) combined with chemotherapeutic drugs significantly inhibit SCLC tumor growth. Mechanistically, CDK4/6is do not function through the classic Retionblastoma1 (RB) dependent axis in SCLC. CDK4/6is induce impair autophagy through the AMBRA1-lysosome signaling pathway. The upregulated AMBRA1 protein expression leads to CDK6 degradation via autophagy, and the following TFEB and TFE3 nuclear translocation inhibition leading to the lysosome-related genes levels downregulation. Moreover, it is found that the expression of CDK6 is higher in SCLC tumors than in normal tissue and it is associated with the survival and prognosis of SCLC patients. Finally, these findings demonstrate that combining CDK4/6is with chemotherapy treatment may serve as a potential therapeutic option for SCLC patients.

Citing Articles

CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer.

Wen Y, Sun X, Zeng L, Liang S, Li D, Chen X Adv Sci (Weinh). 2024; 11(38):e2400666.

PMID: 39136283 PMC: 11481398. DOI: 10.1002/advs.202400666.

References

Klein M, Kovatcheva M, Davis L, Tap W, Koff A . CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. 2018; 34(1):9-20. PMC: 6039233. DOI: 10.1016/j.ccell.2018.03.023. View

Barraco R . Cardiorespiratory responses following electrical stimulation of caudal sites in the rat medulla. Brain Res Bull. 1989; 23(4-5):299-310. DOI: 10.1016/0361-9230(89)90213-x. View

Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P . Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv. 2020; 6(25):eabb2210. PMC: 7360435. DOI: 10.1126/sciadv.abb2210. View

Braal C, Jongbloed E, Wilting S, Mathijssen R, Koolen S, Jager A . Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs. 2020; 81(3):317-331. PMC: 7952354. DOI: 10.1007/s40265-020-01461-2. View

Lai A, Sorrentino J, Dragnev K, Weiss J, Owonikoko T, Rytlewski J . CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020; 8(2). PMC: 7534680. DOI: 10.1136/jitc-2020-000847. View

OLeary B, Finn R, Turner N . Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016; 13(7):417-30. DOI: 10.1038/nrclinonc.2016.26. View

Wang Y, Zhi Y, Jin Q, Lu S, Lin G, Yuan H . Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018; 61(4):1499-1518. DOI: 10.1021/acs.jmedchem.7b01261. View

Puertollano R, Ferguson S, Brugarolas J, Ballabio A . The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J. 2018; 37(11). PMC: 5983138. DOI: 10.15252/embj.201798804. View

Tsoukalas N, Aravantinou-Fatorou E, Baxevanos P, Tolia M, Tsapakidis K, Galanopoulos M . Advanced small cell lung cancer (SCLC): new challenges and new expectations. Ann Transl Med. 2018; 6(8):145. PMC: 5952028. DOI: 10.21037/atm.2018.03.31. View

10.

Kalvari I, Tsompanis S, Mulakkal N, Osgood R, Johansen T, Nezis I . iLIR: A web resource for prediction of Atg8-family interacting proteins. Autophagy. 2014; 10(5):913-25. PMC: 5119064. DOI: 10.4161/auto.28260. View

11.

Yin Q, Jian Y, Xu M, Huang X, Wang N, Liu Z . CDK4/6 regulate lysosome biogenesis through TFEB/TFE3. J Cell Biol. 2020; 219(8). PMC: 7401801. DOI: 10.1083/jcb.201911036. View

12.

Ko J, Winslow M, Sage J . Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2020; 13(1):e13122. PMC: 7799359. DOI: 10.15252/emmm.202013122. View

13.

Uzhachenko R, Bharti V, Ouyang Z, Blevins A, Mont S, Saleh N . Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 2021; 35(1):108944. PMC: 8383195. DOI: 10.1016/j.celrep.2021.108944. View

14.

Weiss J, Goldschmidt J, Andric Z, Dragnev K, Gwaltney C, Skaltsa K . Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clin Lung Cancer. 2021; 22(5):449-460. DOI: 10.1016/j.cllc.2021.03.010. View

15.

Goel S, DeCristo M, McAllister S, Zhao J . CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018; 28(11):911-925. PMC: 6689321. DOI: 10.1016/j.tcb.2018.07.002. View

16.

Hsieh F, Chen Y, Hung M, Chu P, Tsai M, Chen L . Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner. Mol Oncol. 2017; 11(8):1035-1049. PMC: 5537702. DOI: 10.1002/1878-0261.12072. View

17.

Simoneschi D, Rona G, Zhou N, Jeong Y, Jiang S, Milletti G . CRL4 is a master regulator of D-type cyclins. Nature. 2021; 592(7856):789-793. PMC: 8875297. DOI: 10.1038/s41586-021-03445-y. View

18.

Casimiro M, Di Sante G, Di Rocco A, Loro E, Pupo C, Pestell T . Cyclin D1 Restrains Oncogene-Induced Autophagy by Regulating the AMPK-LKB1 Signaling Axis. Cancer Res. 2017; 77(13):3391-3405. PMC: 5705201. DOI: 10.1158/0008-5472.CAN-16-0425. View

19.

Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott R . A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013; 24(2):167-81. PMC: 3743049. DOI: 10.1016/j.ccr.2013.07.012. View

20.

Dai M, Boudreault J, Wang N, Poulet S, Daliah G, Yan G . Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways. Cancer Res. 2020; 81(5):1332-1346. DOI: 10.1158/0008-5472.CAN-20-2121. View